Direct in vivo evaluation of tumor VEGFR in response to treatment with pazopanib: A novel molecular imaging study. Assessment of early vascular effects of the angiogenesis inhibitor sunitinib (SU) in ...
The risk and impact of cardiovascular (CV) adverse events (AEs) in long-term users of tyrosine kinase inhibitors (TKIs) for chronic myeloid leukaemia (CML) is highlighted in a review published in the ...
The first subject expected to be dosed by year-end Company announces OTX-TKI trade name AXPAXLI BEDFORD, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a ...
BEDFORD, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback